Advisory Board


Michael K. Bauer – MSc, PhD

Expert in Drug Development.

Affiliation

SVP, Head of R&D Operations at Genmab

Biosketch

Education:

  • University of Stuttgart-Hohenheim, MSc
  • University of Göttingen, PhD

Michael Karl Bauer joined ImmuMap's team of advisors in 2020 to help steer the company's clinical activities for its pharmaceutical clients. Dr. Bauer has over 20 years of experience in pre-clinical and clinical-stage drug development. He also spent time in Scientific licensing and Venture Capital. He is an author of more than 50 scientific publications. Currently Dr. Bauer serves as Senior Vice President and Head of Operations R&D of Genmab.

Jeppe R. Andersen – MSc, MBA

Expert in Clinical studies and drug development.

Affiliation

CEO, Nordic Bioscience Clinical Development

Biosketch

Education:

  • University of Copenhagen, MSc
  • Smartly School of Business, MBA

Jeppe Ragnar Andersen established and joined ImmuMap's advisory branch as of late 2019. Jeppe brings a depth of knowledge in clinical trial conduct on an operational and executive level from 10+ years of experience as lead and head of all aspects pertaining to clinical trials performed by Nordic Bioscience Clinical Development. In addition, Jeppe strengthens ImmuMap's tailor-made services within precision medicine and biomarker development.

Stefan Glück – MD, PhD, FRCPC

Expert in Drug Development & Clinical Research.

Affiliation

Former VP Global Medical Affairs at Celgene

Biosketch

Education:

  • Freie Universität Berlin, MD
  • RWTH Aachen University, MD, PhD

Stefan Glück is a medical oncologist and was VP Global Medical affairs, Early Assets, Immunology and Oncology at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology.

Dr. Glück served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003-2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 to December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Dr. Glück is highly acclaimed in the medical and scientific community with several honorary awards for his contribution both as oncologist and for (co-)authoring 200+ peer-reviewed journal publications, 50+ book chapters, as well as serving as journal and grant reviewer along being a member of several editorial boards.  

Dr. Glück joined our team of advisors in 2020 to provide his expert guidance on how ImmuMap can best assist our clients in achieving the most productive drug development programs for clinical benefit.

Morten Birkeland – MSc, LLM, European Patent Attorney

Expert in Intellectual Property Management.

Affiliation

Owner & Managing Partner at IPTector Consulting

Biosketch

Education:

  • Technical University of Denmark, MSc Chem Eng
  • University of Strasbourg, LL.M.
  • European Patent Institute, European Patent Attorney

Morten Birkeland joined ImmuMap as advisor in 2019 to aid in our efforts to secure intellectual rights of ImmuMap's unique assets. Morten is specialized in leveraging Intellectual property protection for SME ventures.


Get in touch with us at ImmuMap

– Do you have questions about our work?

ImmuMap - DTU Science Park, Diplomvej 377, 2800 Kgs. Lyngby, Denmark - Tel: +45 6178 1882

×
Call Now
Menu
Contact